INCB-106385
- Generic Name
- INCB-106385
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)Advanced Solid TumorsGastrointestinal (GI) Malignancies
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 57
- Registration Number
- NCT04989387
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇧🇪Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium
🇳🇱University Medical Center Groningen, Groningen, Netherlands
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Non Small Cell Lung CancerCastration Resistant Prostate CancerColorectal CancerTriple Negative Breast CancerGastric/ Gastroesophageal JunctionSquamous Carcinoma of the Anal CanalSquamous Cell Carcinoma of Head and NeckPancreatic Ductal AdenocarcinomaOvarian CancerBladder Cancer
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04580485
- Locations
- 🇧🇪
Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium
🇺🇸Cedars-Sinai Medical Center, West Hollywood, California, United States
🇺🇸University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath